- Castle Biosciences (CSTL, Financial) to present innovative data on TissueCypher Barrett's Esophagus test at Digestive Disease Week 2025.
- The company aims to improve esophageal cancer risk stratification and management for Barrett's esophagus patients.
- Educational sessions highlight the potential impact on clinical practices and management paradigms.
Castle Biosciences (CSTL) is set to showcase groundbreaking data on its TissueCypher Barrett’s Esophagus test at the Digestive Disease Week (DDW) 2025 annual meeting, which will take place in San Diego from May 3 to May 6. The company will present two insightful posters illustrating the test's prowess in identifying patients with Barrett's esophagus who are at an elevated risk of progressing to esophageal cancer.
A product theater, featuring a panel of prominent gastroenterologists, will discuss clinical practice models aimed at preventing Barrett's esophagus from advancing to esophageal adenocarcinoma (EAC). This aligns with Castle Biosciences' focus on improving patient care through advanced diagnostic strategies that go beyond the traditional "wait and see" approach commonly used in managing Barrett’s esophagus.
The featured posters at DDW 2025 include research on TissueCypher's ability to detect missed neoplasia in non-dysplastic Barrett's esophagus and provide enhanced risk stratification for affected patients. This research is supported by collaborative efforts with the American Society for Gastrointestinal Endoscopy (ASGE) and leading clinical experts from prestigious institutions such as Johns Hopkins, UCLA, and Northwestern.
The engagement strategy at DDW 2025 includes multiple educational sessions intended to showcase the potential of the TissueCypher test to alter the risk management and clinical treatment landscape for Barrett's esophagus. This includes the expert panel discussion, "The Time is Now: A Clinical Practice Model to Help Prevent Progression from Barrett's to EAC," scheduled for May 4.
Castle Biosciences is actively working to build clinical credibility through expert engagement, with the intent to drive broader adoption and guideline inclusion for their TissueCypher test in the future. The company's efforts are directed toward transforming the management of Barrett's esophagus, potentially offering more personalized and effective surveillance for patients most at risk of cancer progression.
